Protagonist Therapeutics, Inc. (PTGX) Documents: SEC Filings, Investor Presentations & Press Releases

Protagonist Therapeutics, Inc. (PTGX) documents, SEC filings and the IR site together: 103 documents, newest first; latest 2026-08-05. Read in-app with summaries. First-party data.

Documents — U.S. SEC EDGAR and the company's IR site

Date	Type	Document
2026-08-05	8-K	Form 8-K, Item 2.02 results
2026-08-05	10-Q	Form 10-Q for the quarter ended Jun 30
2026-06-18	8-K	Form 8-K, Item 5.02
2026-05-05	8-K	Form 8-K, Item 2.02 results
2026-05-05	10-Q	Form 10-Q for the quarter ended Mar 31
2026-04-28	Proxy	Definitive proxy statement
2026-02-25	8-K	Form 8-K, Item 2.02 results
2026-02-25	10-K	Annual report on Form 10-K, FY25
2026-01-12	8-K	Form 8-K, Item 7.01
2025-11-06	8-K	Form 8-K, Item 2.02 results
2025-11-06	10-Q	Form 10-Q for the quarter ended Sep 30
2025-08-06	8-K	Form 8-K, Item 2.02 results
2025-08-06	10-Q	Form 10-Q for the quarter ended Jun 30
2025-06-26	8-K	Form 8-K, Item 5.07
2025-05-06	8-K	Form 8-K, Item 2.02 results
2025-05-06	10-Q	Form 10-Q for the quarter ended Mar 31
2025-04-29	Proxy	Definitive proxy statement
2025-03-20	8-K	Form 8-K, Item 8.01
2025-03-11	8-K	Form 8-K/A, Item 8.01
2025-03-03	8-K	Form 8-K, Item 8.01
2025-02-21	8-K	Form 8-K, Item 2.02 results
2025-02-21	10-K	Annual report on Form 10-K, FY24
2025-01-06	8-K	Form 8-K, Item 5.02
2024-11-18	8-K	Form 8-K, Item 1.01
2024-11-07	8-K	Form 8-K, Item 2.02 results
2024-11-07	10-Q	Form 10-Q for the quarter ended Sep 30
2024-09-20	8-K	Form 8-K, Item 5.02
2024-08-06	8-K	Form 8-K, Item 2.02 results
2024-08-06	10-Q	Form 10-Q for the quarter ended Jun 30
2024-06-27	Press release	Protagonist Therapeutics Set to Join S&P SmallCap 600
2024-06-26	8-K	Form 8-K, Item 5.03
2024-05-07	8-K	Form 8-K, Item 2.02 results
2024-05-07	10-Q	Form 10-Q for the quarter ended Mar 31
2024-04-26	Proxy	Definitive proxy statement
2024-02-27	8-K	Form 8-K, Item 2.02 results
2024-02-27	10-K	Annual report on Form 10-K, FY23
2024-01-31	8-K	Form 8-K, Item 1.01
2024-01-16	8-K	Form 8-K, Item 8.01
2024-01-08	8-K	Form 8-K, Item 7.01
2023-11-27	Press release	Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with D

PTGX overview · PTGX earnings · PTGX financials · PTGX KPIs · PTGX ownership · PTGX peers

Data sourced from U.S. SEC EDGAR and the company's investor-relations site. Not personalized investment advice.